Albendazole is NOT contraindicated during lactation
Albendazole can be used during breastfeeding, as concentrations in breast milk are low, there are no reports of adverse effects in breastfed infants, and the benefits of breastfeeding should be weighed against the mother's clinical need for treatment. 1
FDA Labeling Guidance
The FDA drug label explicitly states that albendazole and its active metabolite (albendazole sulfoxide) are present in low concentrations in human breast milk 1. Critically:
- No adverse effects have been reported in breastfed infants
- No information exists suggesting negative effects on milk production
- The label recommends considering "the developmental and health benefits of breastfeeding along with the mother's clinical need for albendazole" 1
This is not a contraindication—rather, it's a risk-benefit assessment framework.
Clinical Context
Key Pharmacokinetic Factors
- Albendazole has poor oral bioavailability and is rapidly converted to its sulfoxide metabolite before reaching systemic circulation 1
- The parent drug concentrations in plasma are "negligible or undetectable" 1
- Even if present in milk, the infant's exposure would be minimal due to the drug's poor absorption characteristics
European vs. US Guidance Discrepancy
While European guidance has historically recommended discontinuing breastfeeding when taking albendazole 2, this appears to be based on limited data rather than documented harm. The FDA labeling (most recent, 2026) takes a more nuanced approach that does not contraindicate breastfeeding 1.
Practical Recommendations
When albendazole is clinically necessary:
- Continue breastfeeding while monitoring the infant for any unusual symptoms
- The short treatment duration for most parasitic infections (single dose or 3-day course) further minimizes any theoretical risk
- Document the clinical indication and discuss the risk-benefit ratio with the patient
Common pitfall to avoid: Do not automatically discontinue breastfeeding based solely on older European guidance when the FDA labeling and available evidence support compatibility with appropriate counseling.
The safety profile of albendazole in mass administration programs (affecting millions of patients) shows predominantly mild gastrointestinal effects when they occur 3, and these have not been reported in breastfed infants despite widespread use.